NEW YORK, NY--(Marketwire - February 05, 2013) - Tonix Pharmaceuticals Holding Corp. (TNXP) ("TONIX" or "the Company"), a specialty pharmaceutical company developing novel treatments for challenging disorders of the central nervous system, including fibromyalgia ("FM") and post-traumatic stress disorder ("PTSD"), today announced its participation in two upcoming conferences.
Seth Lederman, M.D., TONIX's Chief Executive Officer, will present at the 15th Annual BIO CEO and Investor Conference at the Waldorf Astoria Hotel in New York City, on Monday, February 11, 2013, at 11:30 am Eastern Time in the Basildon Room. The Company's presentation will be webcast via the Company's website at www.tonixpharma.com.
Leland J. Gershell, M.D., Ph.D., TONIX's Chief Financial Officer, will participate at the New York CEO Conference at Apella Event Space at Alexandria Center in New York City on Wednesday, February 13, 2013. Dr. Gershell will serve on the 'Small Cap' panel at 4:30 pm Eastern Time.
Dr. Lederman stated, "The first efficacy and safety trial of TNX-102 SL in FM is set to commence in the first half of 2013, which we believe will set the pace for our accelerated growth this year and beyond. We expect to report results from this trial, which may serve as one of two registrational studies for TNX-102 SL in FM, in the first quarter of 2014. We look forward to sharing our business model, marketing plan, and additional information at these premier events."
About Tonix Pharmaceuticals Holding Corp.
TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX's core technology improves the quality of sleep in patients with chronic pain syndromes, which is believed to translate into reductions in pain and other symptoms. An Investigational New Drug Application ("IND") has been filed for the Company's lead product candidate, TNX-102 SL, a novel under-the-tongue tablet formulation of cyclobenzaprine, the active ingredient in two U.S. Food and Drug Administration ("FDA")-approved muscle relaxants. TONIX expects to begin a registrational clinical study of TNX-102 SL for FM in the first half of 2013. TONIX expects to file a second IND for PTSD in the first half of 2013, and to conduct a Phase 2 trial for this indication in the second half of 2013. To learn more, please visit www.tonixpharma.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on TONIX's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 30, 2012 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.